BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21751187)

  • 21. Prostate-specific antigen bounce after curative brachytherapy for early-stage prostate cancer: A study of 274 African-Caribbean patients.
    Leduc N; Atallah V; Creoff M; Rabia N; Taouil T; Escarmant P; Vinh-Hung V
    Brachytherapy; 2015; 14(6):826-33. PubMed ID: 26489920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK.
    Dickinson PD; Malik J; Mandall P; Swindell R; Bottomley D; Hoskin P; Logue JP; Wylie JP
    BJU Int; 2014 May; 113(5):748-53. PubMed ID: 24053230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces?
    Thompson A; Keyes M; Pickles T; Palma D; Moravan V; Spadinger I; Lapointe V; Morris WJ
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):415-21. PubMed ID: 20133083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.
    Ciezki JP; Reddy CA; Garcia J; Angermeier K; Ulchaker J; Mahadevan A; Chehade N; Altman A; Klein EA
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):512-7. PubMed ID: 16213667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PSA bounce versus biochemical failure following prostate brachytherapy.
    Zelefsky MJ
    Nat Clin Pract Urol; 2006 Nov; 3(11):578-9. PubMed ID: 17088921
    [No Abstract]   [Full Text] [Related]  

  • 26. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy.
    Sandler HM; Dunn RL; McLaughlin PW; Hayman JA; Sullivan MA; Taylor JM
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):629-33. PubMed ID: 11020557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy.
    Joseph J; Al-Qaisieh B; Ash D; Bottomley D; Carey B
    BJU Int; 2004 Dec; 94(9):1235-8. PubMed ID: 15610096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    BJU Int; 2003 Jan; 91(1):23-9. PubMed ID: 12614244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrospective analysis after low-dose-rate prostate brachytherapy with permanent (125)I seed implant: clinical and dosimetric results in 70 patients.
    Chiumento C; Montagna A; Clemente S; Cozzolino M; Fusco V
    Tumori; 2011; 97(3):335-40. PubMed ID: 21789012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer - focus on overall survival.
    Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
    Radiat Oncol; 2017 Jun; 12(1):98. PubMed ID: 28615058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose rate brachytherapy compared with open radical prostatectomy for the treatment of high-risk prostate cancer: 10 year biochemical freedom from relapse.
    Savdie R; Symons J; Spernat D; Yuen C; Pe Benito RA; Haynes AM; Matthews J; Rasiah KK; Jagavkar RS; Yu C; Fogarty G; Kattan MW; Brenner P; Sutherland RL; Stricker PD
    BJU Int; 2012 Dec; 110 Suppl 4():71-6. PubMed ID: 23194129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy.
    Crook J; Gillan C; Yeung I; Austen L; McLean M; Lockwood G
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):426-33. PubMed ID: 17869662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure].
    Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
    Cancer Radiother; 2007 May; 11(3):105-10. PubMed ID: 17158082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy.
    Ding W; Lee J; Chamberlain D; Cunningham J; Yang L; Tay J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):962-7. PubMed ID: 22494584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Sun LL; Moul JW; Freedland SJ
    Int J Urol; 2010 Nov; 17(11):914-22. PubMed ID: 20880361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival.
    Lo AC; Morris WJ; Lapointe V; Hamm J; Keyes M; Pickles T; McKenzie M; Spadinger I
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):87-93. PubMed ID: 24331654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy.
    Potters L; Huang D; Fearn P; Kattan MW
    Brachytherapy; 2003; 2(1):26-31. PubMed ID: 15062160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical outcome for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation.
    Merrick GS; Butler WM; Lief JH; Galbreath RW; Adamovich E
    Cancer J; 2002; 8(4):322-7. PubMed ID: 12184410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.